alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D]

What the CMS Formulary Data Shows for alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D]

Per the CMS 2026 Part D formulary file, alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D] (RxNorm concept RXCUI 904495, generic name alendronic acid) appears on 4 distinct formulary files spanning 49 Medicare Part D plan offerings - 1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 4, with a cross-plan average of Tier 3.3.

Real-world access to alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 75% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 642 Part D beneficiaries filled alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D] in 2023, with total plan-and-beneficiary spending of $603,530 and an average per-beneficiary annual cost of $940.08. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry alendronic acid 70 MG / cholecalciferol 2800 UNT Oral Tablet [Fosamax Plus D] today.